Use of VM-26 as a single agent in the treatment of renal carcinoma


    loading  Checking for direct PDF access through Ovid

Abstract

VM-26 WAS ADMINISTERED to 13 patients with metastatic adenocarcinoma of the kidney. Twelve of the 13 patients were assessable. The remaining patient was nonevaluable due to early death as defined in the protocol. No responses were observed in any of the 12 patients. Nonhematological toxicity was mild except for one instance of life-threatening hypotension, occurring during the infusion of VM-26. Significant leukopenia (<3000/mm3) occurred in 29% of courses and significant thrombocytopenia (<100,000/mm3) occurred in 14% of courses. Further studies using VM-26 in renal cell carcinoma do not seem warranted.

    loading  Loading Related Articles